This case highlights the effectiveness of the triple-regimen of vemurafenib, irinotecan, and cetuximab as a treatment option for BRAF<sup>V600E</sup>-mutant CRC, which is a treatment regimen based on the SWOG 1406 trial, and also demonstrates the synergistic role of BRAF<sup>V600E</sup> inhibitors and EGFR inhibitors in the treatment of BRAF<sup>V600E</sup>-mutant CRC. This evidence concerns the gene BRAF and colorectal carcinoma.